The challenge of post-implementation surveillance for novel meningococcal vaccines

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Snape, Matthew D ^a   Medini, Duccio ^c   Halperin, Scott A ^d   DeTora, Lisa ^e   Drori, Jonathan ^f   Moxon, E Richard ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d DALHOUSIE UNIVERSITY   (Canada)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^f Changing Media   (United Kingdom)

Author keywords

Meningococcal; Serogroup b; Surveillance; Vaccine

Indexed keywords

4C NEISSERIA MENINGITIDIS SEROGROUP B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); DIPHTHERIA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; IMMUNOGENICITY; MEMBRANE VESICLE; MENINGOCOCCOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PERTUSSIS; PNEUMOCOCCAL INFECTION; POST IMPLEMENTATION SURVEILLANCE; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; TETANUS; VACCINATION;

HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PRODUCT SURVEILLANCE, POSTMARKETING; SENTINEL SURVEILLANCE;

EID: 84861122838     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.126     Document Type: Article

References (47)

1. Levine O.S., Knoll M.D., Jones A., Walker D.G., Risko N., Gilani Z. Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 2010, 23(3):236-241.
2. Pace D., Pollard A.J., Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(Suppl. 2):B30-B41.
3. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010, 10(2):112-124.
4. Kelly D.F., Moxon E.R., Pollard A.J. Haemophilus influenzae type b conjugate vaccines. Immunology 2004, 113(2):163-174.
5. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326(7385):365-366.
6. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(10):760-768.
7. McVernon J., Andrews N., Slack M.P., Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003, 361(9368):1521-1523.
8. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17(6):919-929.
9. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):379-389.
10. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107(45):19490-19495.
11. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
12. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69(3):1568-1573.
13. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(24):5093-5107.
14. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29(11):e71-e79.
15. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
16. Harris S.L., Zhu D., Murphy E., McNeil L.K., Wang X., Mayer L.W., et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum Vaccin 2011, 7(Suppl.):68-74.
17. ClinicalTrials.gov. A trial to assess the safety, tolerability and immunogenicity of Repevax and rLP2086 vaccine when given together in healthy subjects aged >=11 to <19 years NCT01323270.
18. Giuliani M.M., Biolchi A., Serruto D., Ferlicca F., Vienken K., Oster P., et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010, 28(31):5023-5030.
19. Gossger N., Snape M.D., Yu L.-M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant meningococcal serogroup B vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. JAMA 2012, 307(6):573-582.
20. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Muñoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379(9816):617-624. Epub 2012 Jan 18.
21. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
22. Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. International Pathogenic Neisseria Conference, Banff, Canada; 2010.
23. Jacobsson S., Hedberg S.T., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009, 27(10):1579-1584.
24. Beernink P.T., Welsch J.A., Harrison L.H., Leipus A., Kaplan S.L., Granoff D.M. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007, 195(10):1472-1479.
25. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
26. Brunelli B., Del Tordello E., Palumbo E., Biolchi A., Bambini S., Comanducci M., et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine 2011, 29(5):1072-1081.
27. Seib K.L., Brunelli B., Brogioni B., Palumbo E., Bambini S., Muzzi A., et al. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 2011, 79(2):970-981.
28. Donnelly J., Medini D., Giuliani M.M., Boccadifuoco G., Stella M., Frosi G., et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci 2011, European Meningococcal Disease Society EMGM, Ljubljana, Slovenia.
29. Smith H., Nissen M., Sloots T., Rockett R., Gilchrist S., Orlandi L., et al. Estimating the potential strain coverage in Australia of a multicomponent vaccine targeting serogroup B meningococci. 2011, World Society for Pediatric Infectious Diseases, Melbourne, Australia.
30. Ramsay M.E., Andrews N., Kaczmarski E.B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001, 357(9251):195-196.
31. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166(7):817-823.
32. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2007; 2010 http://ecdc.europa.eu/en/publications/Publications/101011_SUR_Surveillance_of_invasive_bacterial_diseases_in_Europe_2007.pdf.
33. Novartis Vaccine and Diagnostics Carriage Trial. ClinicalTrials.gov NCT01214850.
34. Maiden M.C., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359(9320):1829-1831.
35. Trotter C., Ramsay M., Gray S., Fox A., Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006, 6:616-617.
36. Esposito S., Vesikari T., Kimura A., Ypma E., Toneatto D., Dull P.M. Tolerability of a three-dose schedule of an investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. International Pathogenic Neisseria Conference 2010.
37. Tatley M.V., Kunac D.L., McNicholas A., Zhou L., Ballantyne S., Ashton J., et al. The intensive vaccines monitoring programme (IVMP): an electronic system to monitor vaccine safety in New Zealand. Vaccine 2008, 26(22):2746-2752.
38. Brighton Collaboration. https://brightoncollaboration.org/public.
39. Medicines and Healthcare Products Regulatory Agency Yellow Card Scheme. yellowcard.mhra.gov.uk.
40. Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination. 2011 http://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html.
41. Macdonald N.E., Smith J., Appleton M. Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system?. Biologicals 2011, Oct 10 [Epub ahead of print].
42. Williams G. Angel of death: the story of smallpox 2010, Palgrave MacMillan.
43. Goldacre B. Bad Science 2009, Harper Perennial, London.
44. Opel D.J., Diekema D.S., Lee N.R., Marcuse E.K. Social marketing as a strategy to increase immunization rates. Arch Pediatr Adolesc Med 2009, 163(5):432-437.
45. Bland M., Clear G.M., Grogan A., Hoare K., Waldock J. Mum's the word: factors that influenced young adults' participation in the New Zealand Meningococcal B immunisation programme. N Z Med J 2009, 122(1307):30-38.
46. Turner N.M., York D.G., Petousis-Harris H.A. The use and misuse of media headlines: lessons from the MeNZB immunisation campaign. N Z Med J 2009, 122(1291):22-27.
47. Watson P.B., Yarwood J., Chenery K. Meningococcal B: tell me everything you know and everything you don't know. New Zealanders' decision-making regarding an immunisation programme. N Z Med J 2007, 120(1263):U2751.